<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261102</url>
  </required_header>
  <id_info>
    <org_study_id>MP-37-2017-2793</org_study_id>
    <nct_id>NCT03261102</nct_id>
  </id_info>
  <brief_title>TDM Guided Early Optimization of ADAL in Crohn's Disease</brief_title>
  <official_title>Therapeutic Drug Monitoring Guided Early Optimization of Adalimumab in Crohn's Disease; A Randomized Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>waqqas.afif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the influence of early therapeutic drug monitoring and dose optimization on
      disease outcome in Crohn's patients treated with Adalimumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Some of the participants, care providers and investigators will eventually, in the course of the study, have knowledge of the arm they were assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieved remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission will be scored by a Harvey-Bradshaw Index &lt; 5 AND Biochemical remission will be scored by C-reactive protein &lt; 5 mg/l OR Fecal calprotectin &lt;250 μg/g (combination endpoint)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieved clinical response</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Clinical response will be evaluated by a decreased in Harvey-Bradshaw Index score AND a decreased level of C-reactive protein OR Fecal calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic drug monitoring</measure>
    <time_frame>At Week 8, 12</time_frame>
    <description>Adalimumab drug concentration at week 8 and 12 AND proportion of subjects with antibody to Adalimumab at Week 8 and 12 on the rate i. Clinical response/remission (HBI&lt;5) ii. Biochemical response/remission (CRP within normal reference range) iii. Endoscopic response (SES-CD reduction of ≥50% from baseline) / remission (SES-CD ≤3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of steroid free subjects</measure>
    <time_frame>At Week 12</time_frame>
    <description>Steroid free defined as patients being steroid free at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects well-being</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>Subjects well-being will be scored using the validated questionnaire Short inflammatory bowel disease questionnaire (SIBDQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complications</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rates of complications, including hospitalization, surgery, adverse reaction, and corticosteroid use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Drug Monitoring</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Standard clinical care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab induction as per standard clinical care:
Week 0: 160 mg SC
Week 2: 80 mg SC
Followed by 40 mg SC every 2 weeks' maintenance therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Same as Standard clinical care Arm, except:
If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week
If ADAL trough &gt;15 μg/ml, no dose escalation and continued standard of care dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Standard clinical care</arm_group_label>
    <arm_group_label>Active optimization</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older.

          -  Crohn's disease diagnosed based on standard objective methodology (clinical,
             biochemical, endoscopic, histological and radiological correlation).

          -  Active disease based on Harvey Bradshaw Index (HBI &gt;5) and elevated C-reactive protein
             (CRP) (&gt;normal reference range for local laboratory) OR fecal calprotectin (FCP) (&gt;250
             µg/g)

          -  Due to commence treatment with ADAL.

        Exclusion Criteria:

          -  Severe co-existing cardiopulmonary, hepatic, renal, neurologic, or rheumatologic
             disease.

          -  History of active HIV, hepatitis B or C infection,

          -  Patients with ileostomy/colostomy, ileal-pouch anal anastomosis or severe perianal
             fistulising disease.

          -  Pregnancy

          -  Prior exposure to ADAL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waqqas Afif, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolyne Lemieux, BN, RN</last_name>
    <phone>(514) 934-1934</phone>
    <phone_ext>45699</phone_ext>
    <email>carolyne.lemieux@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Smith, RN</last_name>
    <phone>(514) 934-1934</phone>
    <phone_ext>45699</phone_ext>
    <email>meghan.smith@muhc.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary Medical Center (UCMC)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nima Hamidi</last_name>
      <email>nimahamidi@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Cynthia Seow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norina E Ramos</last_name>
      <email>ramosnorina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Greg Rosenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre (LHSC) University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Prins, RN</last_name>
      <phone>(519) 685-8500</phone>
      <email>Heather.Prins@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Reena Khanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, IBD Centre of Excellence</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Tessier</last_name>
      <phone>(613) 737-8899</phone>
      <phone_ext>73035</phone_ext>
      <email>metessier@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Sanjay Murthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Hospital Center (MUHC)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyne Lemieux, BN, RN</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>45699</phone_ext>
      <email>carolyne.lemieux@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Meaghan Smith, RN</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>45699</phone_ext>
      <email>meaghan.smith@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Waqqas Afif, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talat Bessissow, MDCM, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Bitton, MDCM, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Che-yung Jeff Chao, MBChB, FRACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Restellini-Kherad</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Guillet</last_name>
      <phone>(819) 346-1110</phone>
      <phone_ext>12812</phone_ext>
      <email>cguillet.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Joannie Ruel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>waqqas.afif</investigator_full_name>
    <investigator_title>Dr. Waqqas Afif MD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Crohn</keyword>
  <keyword>adalimumab</keyword>
  <keyword>ADAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

